OTCMKTS:CHGCY Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis $21.87 -0.24 (-1.09%) As of 07/24/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chugai Pharmaceutical alerts:Sign Up Key Stats Today's Range$21.34▼$23.5350-Day Range$21.82▼$25.3752-Week Range$19.50▼$34.84Volume324,333 shsAverage Volume251,742 shsMarket Capitalization$71.98 billionP/E Ratio23.77Dividend Yield2.83%Price TargetN/AConsensus RatingBuy Company Overview Chugai Pharmaceutical Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support. Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines. Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.AI Generated. May Contain Errors. Read More Chugai Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreCHGCY MarketRank™: Chugai Pharmaceutical scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingBuy Consensus RatingChugai Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 2 strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChugai Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Chugai Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth30.61% Earnings GrowthEarnings for Chugai Pharmaceutical are expected to grow by 30.61% in the coming year, from $0.98 to $1.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chugai Pharmaceutical is 23.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Chugai Pharmaceutical is 23.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.Price to Book Value per Share RatioChugai Pharmaceutical has a P/B Ratio of 5.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Chugai Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverChugai Pharmaceutical has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chugai Pharmaceutical has recently increased by 109.10%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldChugai Pharmaceutical pays a meaningful dividend of 2.84%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthChugai Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Chugai Pharmaceutical is 68.89%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 48.44% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.Read more about Chugai Pharmaceutical's dividend. News and Social Media2.0 / 5News Sentiment0.13 News SentimentChugai Pharmaceutical has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Chugai Pharmaceutical this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Institutions0.01% of the stock of Chugai Pharmaceutical is held by institutions.Read more about Chugai Pharmaceutical's insider trading history. Receive CHGCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHGCY Stock News HeadlinesChugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call TranscriptJuly 24 at 4:00 PM | seekingalpha.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call TranscriptJanuary 29, 2026 | seekingalpha.comThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of fading, it transformed into what the Wall Street Journal called a globe-straddling AI supercomputer builder. The company has drawn attention from both Elon Musk and President Trump, who awarded it a five-year, 9.7 billion dollar Pentagon contract. Louis Navellier's system recently assigned it an A rating, the same grade given to Comfort Systems, Supermicro, and Applovin before their historic runs. Louis believes a major event on August 6 could bring new attention to this company's role in AI infrastructure.July 26 at 1:00 AM | InvestorPlace (Ad)Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DMENovember 25, 2025 | finanznachrichten.deChugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug DevelopmentNovember 18, 2025 | msn.comRani Therapeutics Shares Double After Deal With Chugai PharmaOctober 17, 2025 | marketwatch.comRani Therapeutics surges on Chugai licensing deal, private placementOctober 17, 2025 | msn.comRani Therapeutics Holdings Inc. inks $1.085 billion collaboration with Chugai Pharmaceutical Co. Ltd.October 17, 2025 | msn.comSee More Headlines CHGCY Stock Analysis - Frequently Asked Questions How have CHGCY shares performed this year? Chugai Pharmaceutical's stock was trading at $26.27 at the beginning of 2026. Since then, CHGCY stock has decreased by 16.7% and is now trading at $21.87. How were Chugai Pharmaceutical's earnings last quarter? Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) issued its earnings results on Friday, July, 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a trailing twelve-month return on equity of 22.90% and a net margin of 34.98%. How do I buy shares of Chugai Pharmaceutical? Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/24/2026Today7/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:CHGCY CIK1453934 Webwww.chugai-pharm.co.jp Phone(133) 281-6611FaxN/AEmployees7,778Year Founded1925Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio23.77 Forward P/E Ratio22.32 P/E GrowthN/ANet Income$2.91 billion Net Margins34.98% Pretax Margin47.52% Return on Equity22.90% Return on Assets19.45% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio3.82 Sales & Book Value Annual Sales$8.41 billion Price / Sales8.56 Cash Flow$0.95 per share Price / Cash Flow23.06 Book Value$4.12 per share Price / Book5.31Miscellaneous Outstanding Shares3,291,430,000Free FloatN/AMarket Cap$71.98 billion OptionableNot Optionable Beta0.59 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:CHGCY) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chugai Pharmaceutical Co., Ltd. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chugai Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHGCY Stock Alerts